TL;DR
This paper introduces BipotentR, a computational tool that identifies drug targets capable of simultaneously impacting both tumor immunity and a critical oncogenic pathway. They demonstrate its power by discovering Estrogen Related Receptor Alpha (ESRRA) as a promising target that simultaneously disrupts tumor metabolism and enhances anti-tumor immune responses, offering a novel strategy for developing more effective cancer therapies.
What Problem Does This Paper Address?
Cancer cells often develop resistance to single-target therapies by evolving resistance mechanisms or exploiting alternative pathways. The authors propose that "bipotent" drugs, which simultaneously hit two distinct oncogenic pathways, could offer broader clinical benefits, overcome resistance, and be effective in diverse patient populations. However, identifying such bipotent drug targets has been challenging due to a lack of systematic discovery approaches. This paper aims to fill that gap by developing a computational framework to predict these crucial dual-action targets.
Methods
The core innovation is the BipotentR computational approach, which integrates multiple data types to predict bipotent regulators. It consists of two modules:
- Regulation Module: This module uses ChIP-seq data from ~700 transcription factors and chromatin regulators (TFCRs) across ~24,000 samples to estimate their binding affinity to cis-regulatory elements near genes involved in user-defined oncogenic pathways (e.g., energy metabolism, angiogenesis). This module identifies TFCRs that can regulate these specific pathways.
- Immune Module: This module leverages bulk RNA-seq data from patient tumors to assess the immunomodulatory potential of TFCRs by correlating their expression with a proinflammatory signature. Crucially, it then uses single-cell RNA-seq and ATAC-seq data to identify TFCRs that are cancer-cell-specific, meaning they are active in cancer cells but not in CD8+ T cells, thus minimizing off-target effects on the anti-tumor immune response.
By integrating the outputs of these two modules, BipotentR identifies TFCRs that can simultaneously regulate an oncogenic pathway and modulate the immune response in a cancer-cell-specific manner.
Datasets
The study utilized a variety of datasets for training and validation:
- ChIP-seq data: Approximately 24,000 samples were used to identify TFCR binding sites.
- Bulk tumor transcriptomes: Data from ~5,000 human transcriptome datasets and 33 cancer types from The Cancer Genome Atlas (TCGA) were used to assess correlations between predicted regulators and gene expression, and to estimate immunomodulatory potential.
- Single-cell RNA-seq (scRNA-seq) data: Datasets from 5 cancer cohorts and 78 single-cell transcriptome datasets from patients with 27 major cancer types were used to determine cancer-cell specificity of TFCRs.
- Single-cell ATAC-seq (scATAC-seq) data: Used to confirm the functional activity of TFCRs in cancer cells versus CD8+ T cells.
- CRISPR screen data: Published datasets were used to validate the predicted bipotent targets by assessing the effect of gene knockouts on T-cell mediated killing and immune response.
- Patient tumor transcriptomes: 33,000 tumor transcriptomes from TCGA and PRECOG datasets were analyzed to correlate ESRRA activity with clinical immune phenotypes.
- In vivo mouse models: 4T1 (breast cancer) and B16F10 (melanoma) models were used for experimental validation.
Key Insights and Ideas
- The power of dual-action: The paper strongly advocates for the therapeutic potential of targeting two pathways simultaneously, moving beyond single-target approaches.
- Computational integration is key: BipotentR's success lies in its ability to integrate diverse data types (epigenomics, bulk transcriptomics, single-cell transcriptomics) to identify targets with specific, dual functions.
- Cancer-cell specificity is paramount: The immune module's focus on identifying TFCRs active in cancer cells but not CD8+ T cells is crucial for developing therapies that boost immunity without compromising it.
- ESRRA as a prime example: The identification of ESRRA as a top bipotent immune-metabolic regulator highlights the approach's ability to uncover clinically relevant targets. Its dual role in energy metabolism and immune modulation is a compelling proof-of-concept.
- ESRRA's role in resistance: The finding that ESRRA activity is high in immune-suppressive and immunotherapy-resistant tumors suggests it could be a key player in treatment failure, making its inhibition a promising strategy for overcoming resistance.
Key Results
- BipotentR identified 38 candidate immune-metabolic regulators, including 30 immunosuppressive and 8 immunostimulatory TFCRs.
- The top candidate, ESRRA, was shown to inhibit tumor growth through direct effects on energy metabolism and two immune mechanisms: cytokine induction (leading to proinflammatory macrophage polarization) and antigen-presentation stimulation (recruiting CD8+ T cells).
- Inhibition of ESRRA (ESRRAi) in mouse models markedly reduced tumor growth and prevented tumor relapse.
- ESRRAi treatment led to increased infiltration and activation of CD8+ T cells and suppressed regulatory T cells (Tregs).
- ESRRAi also promoted M1 macrophage polarization, shifting them towards a more anti-tumorigenic state.
- Analysis of patient data revealed that high ESRRA activity is associated with immunosuppressive and immunoresistant tumors, suggesting broad clinical relevance.
- The BipotentR approach was also successfully applied to angiogenesis and growth-suppressor pathways, demonstrating its generalizability.
Limitations and Future Work
- Translational challenges: While ESRRAi showed promise in preclinical models, further clinical investigation is required to confirm its efficacy and safety in human patients, particularly in immunotherapy-resistant settings.
- Off-target effects: Although the immune module aims to minimize off-target effects on CD8+ T cells, the possibility of unintended consequences from inhibiting a nuclear receptor like ESRRA warrants careful consideration in drug development.
- Broader pathway exploration: While the paper demonstrates BipotentR's applicability to other pathways, further exploration of these targets and their therapeutic potential is needed.
- Mechanism refinement: While the paper elucidates key mechanisms of ESRRA inhibition, a deeper understanding of the intricate interplay between ESRRA, metabolism, and the immune system could lead to more refined therapeutic strategies.
- BipotentR accessibility: The authors have made BipotentR publicly available, which is a crucial step for enabling further research and drug discovery in this area.
Summary updated